RxDoctor Payments Data

Michelle Ouellette, MD

Cardiovascular Disease · Manchester, NHNPI 1417273871

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Medtronic at 50.2% of the total. Reporting peaked in 2022 at $2,808 and has fallen 68.4% since, to $888 in 2025.

$7,365in general payments, 2019–2025

Across 100 payments — averaging $73.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abiomed$770
  • Cardiovascular Systems Inc.$701
  • Boston Scientific$410
  • Inari Medical, Inc.$349
  • Asahi Intecc USA, Inc.$243
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$3,59649%
  • Food & beverage$3,70050%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,365 in reported general payments places this provider in the 85th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$157,644
Medicare patients
831
Services billed
1,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$180,137
XareltoRivaroxaban28$29,820
Repatha SureclickEvolocumab11$6,068
Metoprolol Succinate401$4,802
Ranolazine ErRanolazine22$3,240
Rosuvastatin Calcium211$2,530
Ezetimibe54$1,450
Atorvastatin Calcium226$1,413
Torsemide39$1,361
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$1,183
Isosorbide Mononitrate ErIsosorbide Mononitrate125$1,102
Potassium Chloride27$1,000
Flecainide Acetate27$989
Amiodarone Hcl18$937
Amlodipine Besylate173$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$180,137120 claims
Johnson & JohnsonXarelto$70$29,82028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →